TEM
Tempus AI, Inc.
September 17, 2026 · intraday
- Rarity
- 1.56
- Peak move
- +15.99%
- Float cap
- $7.3B
Tempus AI is a healthcare technology company that provides AI-enabled diagnostics, including next-generation sequencing, PCR profiling, and anatomic and molecular pathology testing, to healthcare providers, life sciences companies, researchers, and other third parties. It also offers data and applications products that license de-identified clinical, molecular, and imaging data and provide analytics and clinical trial support to pharmaceutical and biotechnology companies.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 2 from SEC or newswire · 0 timed with the moveinsider_saleTempus AI officer Vanessa Kubo filed notice to sell 700 common shares at an average price of $68.85, a market value of $48,195, under a Rule 10b5-1 plan.
SEC144 0001950047-26-009569insider_saleTempus AI insider Ryan Fukushima filed a Form 144 with the SEC on Sept 16, 2026 disclosing a proposed sale of restricted Class A stock.
acquisition_targetTempus AI filed a Form 425 communication about a pending merger on September 15, 2026.
SEC425 0001193125-26-392159guidance_changeAt the Morgan Stanley Global Healthcare Conference on Sept 15, 2026, Tempus AI CEO Eric Lefkofsky said the solid tumor assay list price will rise from $2,923 to $4,500 effective January 1, 2027, adding $80M-$100M annually, with liquid biopsy approval expected in H2 2027 lifting pricing from ~$3,200 to the mid-to-high $7,000s for $250M-$300M.
major_contractTempus AI CEO Eric Lefkofsky said at the Morgan Stanley conference that Tempus signed multiple long-term data licensing agreements worth more than $100 million each with AstraZeneca, Bristol Myers Squibb, GSK, Merck and BioNTech.
executive_remarkTempus AI CEO Eric Lefkofsky, speaking publicly on Sept 14, endorsed slowing AI development, citing self-training models, safety and capital efficiency, while praising Anthropic, OpenAI and SpaceX healthcare efforts.